Isolating Cord Blood Stem Cells via Immunomagnetic Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell research faces challenges such as ethical concerns and immune rejection, and there is a scarcity of embryonic-like stem cells with embryonic-stem cell characteristics from readily available sources, limiting their practical application in therapies for diseases like Parkinson's, diabetes, and cardiovascular disease.
Innovation Solution
Isolation and expansion of hematopoietic-origin cord blood-stem cells (CB-SC) from human umbilical cord blood, which express the CD45 marker and display embryonic and hematopoietic characteristics, allowing for low immunogenicity and immune regulation, enabling their use in various cell types and therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic stem cells are used for therapy, then regenerative potential is improved, but ethical concerns and immune rejection increase
Solution Approach 1:
The patent extracts and isolates a specific stem cell population (CD14 negative, CD45 positive, CD117 positive) from cord blood mononuclear cells, separating them from other cell types including monocytes. This extraction allows the use of stem cells without the ethical concerns associated with embryonic sources, while maintaining their regenerative potential and reducing immune rejection through autologous transplantation.
Solution Approach 2:
The patent uses cord blood mononuclear cells as an intermediary source to obtain stem cells. This intermediary approach allows access to pluripotent stem cells through a readily available, ethically acceptable source (cord blood) rather than directly using embryonic sources, thereby reducing ethical concerns and immune rejection while preserving regenerative capabilities.
2Quantity of substance
If cord blood is used as stem cell source, then availability is improved, but purity of embryonic-like stem cells decreases due to contamination with monocytes
Solution Approach 1:
The patent segments the cord blood mononuclear cell population into distinct subsets based on marker expression. By isolating CD14 negative, CD45 positive, CD117 positive cells, the method separates true embryonic-like stem cells from monocyte contaminants, achieving high purity while maintaining the abundance of stem cells available in cord blood.
Solution Approach 2:
The patent replaces mechanical separation methods with immunomagnetic separation using magnetic beads conjugated to specific antibodies. This allows precise identification and isolation of stem cells based on their surface markers (CD14, CD45, CD117), achieving high purity without the limitations of mechanical approaches.
3Manufacturing precision
If monocytes are removed from cord blood cells, then purity of stem cells is improved, but loss of total cell number increases
Solution Approach 1:
The patent applies local quality selection by targeting specific surface markers (CD14, CD45, CD117) on individual cells. This allows selective isolation of stem cells with the desired marker profile while leaving other cell types in the cord blood sample, thereby achieving high purity without requiring removal of all cells, thus preserving total cell number.
Data Source
AI summary
The present invention is related generally to embryonic-like stem cells isolated from human umbilical cord blood, designated herein as cord blood-stem cells (CB-SC's), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to multiple types of cells. In addition, the CB-SC display low immunogenicity and immune regulation. These cells are, therefore, suitable for use in stem cell-based therapies for the treatment of diseases such as Parkinson's disease, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects, and for preventing, treating and/or reducing an autoimmune disease in a mammalian subject.